Pembrolizumab Yields Lasting Merkel-Cell Carcinoma Responses

April 20, 2016


American Association for Cancer Research

Publication Date

April 20, 2016

Download PDF


In a phase II single-arm study, the PD-1 checkpoint inhibitor pembrolizumab effectively shrank tumors and prolonged survival in more than half of patients with Merkel cell carcinoma. Responses were significantly more durable that those typically seen with chemotherapy.

View the clinical publication